Lumos Diagnostics Holdings (ASX:LDX) Other Financing: A$-0.72 Mil (TTM As of Dec. 2025)


ASX:LDX Lumos Diagnostics Holdings Ltd ASX:LDX
31 GF Score
Price A$0.11
GF Value A$0.02
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Lumos Diagnostics Holdings Other Financing?

Lumos Diagnostics Holdings ASX:LDX 31 Other Financing is A$-0.72 Mil as of Dec. 2025. GuruFocus rates ASX:LDX with a GF Score™ of 31/100 and a GF Value™ of A$0.02 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Lumos Diagnostics Holdings's Other Financing for the six months ended in Dec. 2025 was A$-0.78 Mil.

Lumos Diagnostics Holdings's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.72 Mil.

Lumos Diagnostics Holdings Other Financing Historical Data

* Premium members only.

The historical data trend for Lumos Diagnostics Holdings's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumos Diagnostics Holdings Other Financing Chart

Lumos Diagnostics Holdings Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Other Financing
-26.74 -2.93 -1.90 -1.45

Lumos Diagnostics Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.02 -0.34 -0.69 0.05 -0.78
ASX:LDX
31GF Score
Lumos Diagnostics Holdings Ltd ASX:LDX
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lumos Diagnostics Holdings Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of A$-0.72 Mil mean?
Lumos Diagnostics Holdings (ASX:LDX) has a Other Financing of A$-0.72 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Lumos Diagnostics Holdings and its competitors.
Is Lumos Diagnostics Holdings' Other Financing too high?
Lumos Diagnostics Holdings' current Other Financing is A$-0.72 Mil. Overall, Lumos Diagnostics Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumos Diagnostics Holdings' Other Financing compare to ABT and SYK?
Lumos Diagnostics Holdings' Other Financing of A$-0.72 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Devices & Instruments company?
A good Other Financing depends on the Medical Devices & Instruments industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Lumos Diagnostics Holdings and its competitors. Lumos Diagnostics Holdings's current Other Financing is A$-0.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (ASX:LDX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.11 — trading 425% above its estimated fair value. The current Other Financing is A$-0.72 Mil. Lumos Diagnostics Holdings' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Lumos Diagnostics Holdings (ASX:LDX), the current Other Financing is A$-0.72 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lumos Diagnostics Holdings (ASX:LDX) Overvalued in 2026?

Based on GuruFocus' analysis, Lumos Diagnostics Holdings stock appears to be overvalued. The current stock price of A$0.11 is trading 425% above its estimated GF Value™ of A$0.02. GuruFocus considers Lumos Diagnostics Holdings to be Significantly Overvalued.

Key valuation signals for ASX:LDX:

  • Other Financing: A$-0.72 Mil
  • GF Value™: A$0.02 vs. price of A$0.11 (425% above fair value)
  • GF Score™: 31/100 with 7 warning signs

No single metric tells the full story. See the ASX:LDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lumos Diagnostics Holdings Business Description

Other Exchanges LDXHF:USA
Address 2724 Loker Avenue West, Carlsbad, CA, USA, 92010
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
31GF Score

Get the complete analysis for ASX:LDX

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price
A$0.02
GF Value